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Background
Bibliography
Conclusion and Perspectives: We have identified a novel chemical scaffold, that demonstrates cytotoxic activity in vitro in
a range of human cell lines, including MCF7 and SKBR3 (Breast), DUI145 (Prostate) and A549 (Lung). Excitingly, 012L has not
shown cytotoxicity to normal HEK cells even at a concentration 30 times higher than its IC50 on SKBR3. Tamoxifen, on the other
hand, at its IC50 concentration, has induced apoptosis on 85% of the HEK cells. The decrease in ROS accumulation in a dose-
dependent manner for the compounds of this novel indane scaffold suggests that it might be involved on the cellular apoptosis
induction. Our working hypothesis has been that hybridization of several bioactive fragments results in synergized bioactivity (Figure
2 and 3). The results demonstrate the validity of this hypothesis, showing that the nature and position of substitution together with
stereo-isomeric specificity results in significant increases in bioactivity: e.g. coupling of indan-1-one (IC50 100 µM in SKBR3,
A549, MCF7 and IC50 40.88 µM in DUI45) with fragment A (IC50 100 µM in SKBR3 and MCF7; and IC50 46.4 µM in A549, and
IC50 33.54 µM in DU145) yields a novel chemical scaffold with (IC50 1.04 µM in SKBR3, 14.9 in A549, 26.9 in DUI145 (Prostate)
and 35.7 in MCF7. One hybrid 14b2t compares well with Tamoxifen across the cell lines. Several hybrids are more potent in the
SKBR3 cell line. Future chemical synthesis: We are preparing to couple indanone nuclei with new fragments we have prepared,
that display nanomolar activity across the four cell lines, to generate what we believe will be derivatives with significant nanomolar
dual activities. Future bioactivity evaluation: Initial studies also support the effects of scaffolds against other HER2+ breast
cancer cells, including resistant to conventional treatments. A series of indebt in vitro anti-cancer assessments and in vivo and in vitro
anti-inflammatory studies will be carried out over the next months, to establish MOE and selectivity of these scaffolds.
FROM NATURE TO MEDICINAL CHEMISTRY: ANTICANCER 
ACTIVITY OF NOVEL INDANE SCAFFOLDS
The indane scaffold is of key importance in the natural world. It occurs in a range of biologically active natural products. The natural structures range from simple indanes and indanones with
antibacterial activity e.g. indanone isolated from the cyanobacterium Nostoc1 to the pterosin family of fern and fungal metabolites, which show cytotoxicity toward the Human leukaemia HL-
60 cell line2, 3, to oligomers of resveratrol (3,5,4‘-trihydroxystilbene) e.g. the indane Pauciflorol F isolated from the Dipterocarpaceae.4 The therapeutic potential of indanes becomes more
evident in the area of medicinal chemistry where this scaffold is incorporated into structures that demonstrate therapeutic properties e.g. the indanone Sulindac (Clinoril™; Merck), a non-
teroidal anti-inflammatory that has recently demonstrated anti-proliferative and apoptotic effects.5,6 More recently the tubulin polymerisation inhibitor Indanocine (NIH) has been receiving
attention.7 During the course of our research on indane monomers and dimers, we have noted that the potential of novel indane scaffolds for the treatment of inflammatory disease and cancer
has not been fully exploited. It is also well established that inflammation plays a significant role in the development of cancer.8 The aim of this research project is to combine, experience led
and evidence based, theories with our knowledge of small molecule drug development to generate novel hybrid scaffolds with therapeutic potential for the treatment of cancer and
inflammatory disease. The second fragment of interest, in this study comes from the naturally occurring benzophenones.9 This class of molecules features widely in plants used as anti-tumour
agents in Traditional Herbal Medicinal systems. A range of bioactivities has been established for members of this chemical class, including tubulin binding and P-glycoprotein (P-gp)
modulating activity, the prototypical efflux transporter, implicated in multidrug resistance (MDR).
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Results and Discussion
Methods:
Synthesis and specific compounds: Will not be discussed at this point. Cell Culture: All the cell lines were maintained in a humid chamber at 37 ºC and 5%
CO2 atmosphere. SKBR3 (ATCC HTB-30), MCF7 (ATCC HTB- 22), and DU145(ATCC HTB-81) cells were cultured in RPMI-1640 Medium containing 10%
fetal bovine serum (FBS) and 1% L-Glutamine. A549 (ATCC CCL-185) lung carcinoma cells were grown in Dulbecco′s Modified Eagle′s Medium supplemented
with 5% FBS. HEK(ATCC CRL-1573™; embryonic kidney cells) was grown in Minimum Essential Medium Eagle supplemented with 10 % FBS. Acid
Phosphatase assay: After 5 days of incubation of cells with the drugs, the medium was removed and each well was washed with 100 μL of PBS. Then, 100 μL of
freshly prepared phosphatase substrate (10 mM p-nitrophenol phosphate, Sigma) in 0.1 M sodium acetate (Sigma), 0.1 % triton X-100 pH5.5 (BDH) was added to
each well. The plates were wrapped in tin foil and incubated in the dark at 37º C for 1 hour. The reaction was stopped by the addition of 50 μL of NaOH 1 M to
each well and measuring was obtained in a dual beam plate reader at 405 nm with a reference wavelength of 620 nm.
Figure 3: IC50 comparison of lead compounds 
in HER2+ SKBR3  breast cancer cell line
A novel scaffold designed around an indane nucleus was identified as the chemical target in this study (Fig.1). The scaffold was synthesised by combining a series of small chemical
fragments using a range of spacer molecules. The second major fragment incorporated into the molecule is centered on the small naturally occurring bioactive benzophenone moiety, which
depending on substitution pattern demonstrates a variety of biological properties. Initial studies have led to the development of a synthetic approach that has thus far yielded eight final
products with the desired final chemical scaffold. All products and intermediates have been characterized spectroscopically. The cytotoxicity of the starting fragments and products were
evaluated using the Acid Phosphatase assay, in a series of in vitro cancer cell lines. Coupling of the main molecular fragments and spacers gave rise to compounds with a novel chemical
scaffold. These molecules displayed significant increases in IC50 values in the cell lines under investigation, relative to their component fragments (Figs.2 and 3). Compounds with the new
scaffold induce apoptosis to varying degrees and also demonstrate either inhibition of ROS production or act as a free radical scavenger (Figs. 4 and 5) and cell cycle arrest. A lead
compound has been identified within the series which has displayed the highest IC50 value (1.0 mM) against the HER2+ cell line SKBR3. Current studies are now focussed on this cell line.
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Figure 1: Target Hybrid Scaffold
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Cytotoxicity of optimised hybrid and natural precursors in MCF7 and
SKBR3 (Breast), DUI145 (Prostate) and A549 (Lung) in vitro cell lines
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Figure 2: Cytotoxicity of parent hybrid and natural precursors in MCF7 
and SKBR3 (Breast), DUI145 (Prostate) and A549 (Lung) cell lines
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Figure 4: Flow cytometry analysis of 
Apoptosis induction of lead compound 
over time in SKBR3 cells
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Figure 6: Flow cytometry analysis of Apoptosis induction and Cell cycle arrest in HEK-293 cells (72 h, n=3)
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Figure 5: Flow cytometry analysis of ROS 
accumulation of leading compounds in SKBR3 
cells (24 h, n=3)
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